Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Cambridge Semantics ... driven by Semantic Web technology, and Informa ... and services for the academic and scientific, professional ... joint solution ‘Smart Data Lake for Clinical Trial ... the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... Miami, FL (PRWEB) April 16, 2015 ... therapy cap distribution and physician network in Europe ... marketing company has appointed Fernando Bermúdez, former Business ... Director. , An industry veteran, Mr. Bermúdez’s professional ... by 75% in Spain, while also penetrating the ...
(Date:4/16/2015)... 2015  Schulman Associates IRB, Inc., the industry-leading central ... long-term lease on Laboratory Drive in the heart of ... The location will house review board and service staff, ... reviews and customer service to clients. ... in the deal, while Capital Associates Management, LLC represented ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Schulman IRB to Open Office in Research Triangle Park, N.C. 2The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... European research initiative EUREKA will be represented with its ... of HANNOVER MESSE 2010 (19-23 April). This presentation underlines ... and Development in Hall 2. "We want ... central European platform with respect to the international networking ...
... Md. , and INDIANAPOLIS , Feb. 10 ... Corporation (Nasdaq: UTHR ), announced today that it has ... development of ImmuneWorks, lead compound, IW001, a purified bovine Type ... Fibrosis (IPF) and Primary Graft Dysfunction (PGD) in patients receiving ...
... PLANTATION, Fla. and DALLAS , ... full service Contract Biomanufacturing Company and Macrocyclics, Inc., ... today their collaborative agreement on Chelation and Bioconjugation. ... Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing. ...
Cached Biology Technology:European research initiative EUREKA presented at Research & Technology for the first time 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration 2
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... SAN ANTONIO (Jan. 7, 2011) Resveratrol, a compound ... a study published this week, researchers at the UT ... in which resveratrol exerts these beneficial health effects. ... from cells that manufacture and store fat, the team ...
... January 7, 2011 By rethinking what happens on ... discovered that Bacillus subtilis biofilm colonies exhibit ... liquidsand even vapors. Centimeters across yet only hundreds ... the surfaces of everything from pipes to teeth and ...
... Indiana University-Purdue University Indianapolis has received $943,000 from ... and diversity of future life science researchers. ... Research Mentoring in the Biological Sciences (URM) Program, ... URM is designed to broaden participation of African ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2A pesky bacterial slime reveals its survival secrets 2A pesky bacterial slime reveals its survival secrets 3Increasing diversity of future life science researchers 2